2026-2034年全球氣喘和慢性阻塞性肺病（COPD）市場規模、佔有率、趨勢和成長分析報告

預計氣喘和慢性阻塞性肺病市場將從 2025 年的 422.5 億美元成長到 2034 年的 654.4 億美元，2026 年至 2034 年的複合年成長率為 4.98%。

受空氣污染加劇、菸草消費量增加以及呼吸系統疾病盛行率上升的推動，全球氣喘和慢性阻塞性肺病（COPD）市場正經歷顯著成長。都市化和工業化加劇了空氣品質惡化，導致診斷率上升。製藥公司正投資研發創新吸入器、生物製藥和聯合治療，以改善疾病管理。

關鍵成長要素包括生物目標療法的進步、醫療保健支出的增加以及政府對意識提升的支持。具備數位化監測功能的智慧吸入器的推出提高了患者的用藥依從性和治療效果。擴大臨床研究和增加學名藥的供應進一步增強了市場競爭力。

展望未來，由於個人化治療方案的廣泛應用和診斷能力的提升，市場預計將持續成長。隨著醫療基礎設施的不斷完善，新興市場預計將迎來強勁成長。對長效支氣管擴張劑和抗發炎藥物的持續研究將塑造未來的市場格局，並提升長期獲利能力。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球氣喘與慢性阻塞性肺病（COPD）市場：依疾病分類

• 市場分析、洞察與預測
• 氣喘
• COPD

第5章 全球氣喘與慢性阻塞性肺病（COPD）市場：依藥物分類

• 市場分析、洞察與預測
• 組合藥物
• 短效BETA受體激動劑（SABA）
• 長效BETA2受體激動劑（LABA）
• 白三烯拮抗劑（LTAs）
• 抗膽鹼能促效劑
• 其他

第6章 全球氣喘和慢性阻塞性肺病（COPD）市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第7章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第8章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • GlaxoSmithKline Plc
  • AstraZeneca Plc
  • Hoffmann-La Roche Ltd
  • Vectura Group Plc
  • Organon
  • Abbott Laboratories
  • Boehringer Ingelheim International GmbH
  • Teva Pharmaceutical Industries Ltd
  • Novartis AG
  • Sanofi

The Asthma And COPD Market size is expected to reach USD 65.44 Billion in 2034 from USD 42.25 Billion (2025) growing at a CAGR of 4.98% during 2026-2034.

The Global Asthma And COPD Market is witnessing substantial growth driven by rising air pollution levels, increasing tobacco consumption, and growing prevalence of respiratory disorders. Urbanization and industrialization have contributed to deteriorating air quality, leading to higher diagnosis rates. Pharmaceutical companies are investing in innovative inhalers, biologics, and combination therapies to enhance disease management.

Major growth drivers include advancements in targeted biologic therapies, increased healthcare spending, and supportive government initiatives for respiratory health awareness. The introduction of smart inhalers with digital monitoring features is improving patient adherence and treatment outcomes. Growing clinical research and expansion of generic drug availability are further strengthening market competitiveness.

Looking forward, the market is poised for continued expansion with rising adoption of personalized treatment approaches and improved diagnostic capabilities. Emerging economies are expected to witness strong growth due to expanding healthcare infrastructure. Ongoing research in long-acting bronchodilators and anti-inflammatory agents will likely shape the future landscape and enhance long-term revenue potential.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Diseases

• Asthma
• COPD

By Medication Class

• Combination Drugs
• Short Acting Beta Agonists (SABA)
• Long Acting Beta Agonists (LABA)
• Leukotriene Antagonists (LTA)
• Anticholinergics
• Others

COMPANIES PROFILED

• GlaxoSmithKline Plc, AstraZeneca Plc, HoffmannLa Roche Ltd, Vectura Group Plc, Organon, Abbott Laboratories, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd, Novartis AG, Sanofi
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ASTHMA AND COPD MARKET: BY DISEASES 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Diseases
• 4.2. Asthma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. COPD Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ASTHMA AND COPD MARKET: BY MEDICATION CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Medication Class
• 5.2. Combination Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Short Acting Beta Agonists (SABA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Long Acting Beta Agonists (LABA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Leukotriene Antagonists (LTA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Anticholinergics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ASTHMA AND COPD MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Diseases
  • 6.2.2 By Medication Class
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Diseases
  • 6.3.2 By Medication Class
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Diseases
  • 6.4.2 By Medication Class
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Diseases
  • 6.5.2 By Medication Class
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Diseases
  • 6.6.2 By Medication Class
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL ASTHMA AND COPD INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 GlaxoSmithKline Plc
  • 8.2.2 AstraZeneca Plc
  • 8.2.3 Hoffmann-La Roche Ltd
  • 8.2.4 Vectura Group Plc
  • 8.2.5 Organon
  • 8.2.6 Abbott Laboratories
  • 8.2.7 Boehringer Ingelheim International GmbH
  • 8.2.8 Teva Pharmaceutical Industries Ltd
  • 8.2.9 Novartis AG
  • 8.2.10 Sanofi